Christopher Morabito - Apr 1, 2024 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role
Chief Medical Officer
Signature
/s/ Ben Harshbarger, as attorney-in-fact for Christopher Morabito
Stock symbol
ATXS
Transactions as of
Apr 1, 2024
Transactions value $
-$97,239
Form type
4
Date filed
4/3/2024, 04:05 PM
Previous filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATXS Common Stock Options Exercise $38.7K +10K $3.87* 10K Apr 1, 2024 Direct F1
transaction ATXS Common Stock Sale -$136K -10K -100% $13.59 0 Apr 1, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATXS Stock Option (Right to Buy) Options Exercise $0 -10K -11.11% $0.00 80K Apr 1, 2024 Common Stock 10K $3.87 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.76, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 This option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.